FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Linney Yvonne					2. Issuer Name and Ticker or Trading Symbol Bionano Genomics, Inc [BNGO]										k all applic	able)	g Pers	son(s) to Iss	
(Last) (First) (Middle) C/O BIONANO GENOMICS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 05/04/2020										Officer below)	(give title		Other (s below)	pecify	
9540 TOWNE CENTRE DRIVE, SUITE 100					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) SAN DII	EGO C.	CA 92121												,	X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	tate)	(Zip)																
		Tab	le I - Non-	-Deriva	ative	Se	curities	s Ac	quired, D	isp	osed o	f, or Be	nefic	ially	Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date,			Code (Instr. 5)				4 and Securitie Beneficia		es Form ally (D) of Following (I) (II		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	(A) or (D)		ice	Transact (Instr. 3 a	tion(s)			(III3ti. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative Conversion Date Execution Date, or Exercise (Month/Day/Year) if any			ate, Ti	ansaction of ode (Instr. Derivative			Expiration Date (Month/Day/Year) of S			7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		Derivative Security		9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
				c	ode	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amou or Numl of Share	ber					
Stock Option (right to buy)	\$0.38	05/04/2020			A		80,923		(1)	0	5/04/2030	Common Stock	80,9)23	\$0.00	80,923	3	D	

1. The shares vest in equal monthly installments over a three year period such that the option is fully vested on May 4, 2023, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan).

Remarks:

/s/ Heather Adams, Attorney-

in-fact

** Signature of Reporting Person Date

05/05/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.